Oncotelic Therapeutics Announces CEO To Discuss Proprietary AI Technology at Ibero-American Chatbot Summit
AGOURA HILLS, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) –
Oncotelic Therapeutics, Inc (OTCQB:OTLC) (“Oncotelic”, the “Company” or “We” or “Our”), announced today its Chief Executive Officer (“CEO”), Dr. Vuong Trieu, will be a featured speaker at the upcoming Ibero-American Chatbot and Conversational AI Summit. Dr. Trieu will be discussing the Company’s proprietary chatbots, which have revolutionized the way AI technology is used in the healthcare industry.
Revolutionizing Healthcare with AI
Oncotelic Therapeutics has been at the forefront of utilizing AI technology to improve patient outcomes and streamline healthcare processes. The Company’s proprietary chatbots are designed to assist healthcare professionals in diagnosing and treating patients more efficiently and accurately.
By leveraging the power of artificial intelligence, Oncotelic’s chatbots are able to analyze vast amounts of data quickly and provide personalized treatment recommendations based on each patient’s unique medical history and symptoms. This has the potential to revolutionize the way healthcare is delivered, making it more precise and effective.
Improving Patient Care
Dr. Trieu’s presentation at the Ibero-American Chatbot Summit will showcase how Oncotelic’s AI technology has already had a significant impact on patient care. By reducing the time it takes to diagnose and treat patients, Oncotelic’s chatbots are helping to save lives and improve outcomes for those in need of medical assistance.
Furthermore, Oncotelic’s chatbots have been shown to increase the efficiency of healthcare providers, allowing them to focus more on direct patient care rather than administrative tasks. This not only improves the overall patient experience but also helps to alleviate the burden on healthcare professionals.
Looking Towards the Future
As Oncotelic continues to develop and refine its AI technology, the possibilities for improving patient care are endless. The Company is dedicated to advancing the field of healthcare through innovation and cutting-edge technology, and Dr. Trieu’s presentation at the Ibero-American Chatbot Summit is just the beginning of what promises to be a bright future for Oncotelic Therapeutics.
How will this affect me?
As a consumer of healthcare services, the advancements in AI technology by Oncotelic Therapeutics could greatly benefit you in the future. By streamlining healthcare processes and improving the accuracy of diagnoses and treatment recommendations, you may experience faster and more personalized care that leads to better outcomes.
How will this affect the world?
The impact of Oncotelic Therapeutics’ AI technology on the healthcare industry has the potential to revolutionize the way healthcare is delivered on a global scale. By improving patient care and increasing the efficiency of healthcare providers, this technology could help to address healthcare disparities, reduce costs, and ultimately save lives.
Conclusion
Oncotelic Therapeutics’ announcement of Dr. Trieu’s participation in the Ibero-American Chatbot and Conversational AI Summit is a testament to the Company’s commitment to advancing the field of healthcare through innovative AI technology. The future looks bright for Oncotelic and the many patients who stand to benefit from their groundbreaking advancements.
